Skip to content

The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women

The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01188902
Enrollment
60
Registered
2010-08-26
Start date
2010-08-31
Completion date
2012-08-31
Last updated
2013-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The objectives of the proposed study are to assess the effect of walnut consumption on parameters of lipid metabolism, glucose metabolism, incretins and adipokines, endothelial function and blood pressure in healthy men and healthy postmenopausal women

Interventions

DIETARY_SUPPLEMENTwalnut

walnut consumption 48 g/d

Sponsors

Ludwig-Maximilians - University of Munich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Postmenopausal healthy women and healthy men * Age \> 50 yrs

Exclusion criteria

* Evidence of alcohol, tabacco or drug abuse * Obesity ≥ 35 kg/m2 * Diabetes mellitus * Hypertension * LDL-cholesterol \> 190 mg/dl, Triglycerides \> 350 mg/dl * History of atherosclerotic disease

Design outcomes

Primary

MeasureTime frame
Fasting non-HDL-cholesterol8 weeks

Secondary

MeasureTime frameDescription
area under the triglyceride curve (AUC-TG)8 weeksarea under the plasma triglyceride concentration curve following a standardized oral fat challenge
incremental area under the triglyceride curve (iAUC-TG)8 weeksincremental area under the plasma triglyceride concentration curve following a standardized oral fat challenge
LDL-cholesterol8 weeksfasting plasma LDL-cholesterol concentration
HDL-cholesterol8 weeksfasting plasma HDL-cholesterol concentration
triglyceride8 weeksfasting plasma triglyceride concentration
glucose8 weeksfasting plasma glucose concentration
HOMA8 weeks
insulin8 weeks
HbA1c8 weeks
area under the glucose curve (AUC-glucose)8 weeksarea under the plasma glucose concentration curve following a standardized oral challenge
area under the insulin curve (AUC-insulin)8 weeksarea under the plasma insulin concentration curve following a standardized oral challenge
endothelial function8 weeksPostprandial (mixed meal challenge) endothelial function (flow mediated dilatation, flow-independent dilatation)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026